Professor of Medicine, Institute for Academic Medicine
Weill Cornell Medical College
Dr. Iyer is a Hematologist/Oncologist and has extensive expertise in early phase clinical studies including several first in human anticancer agents; he was part of pivotal studies that led to the FDA approval of the new anti-CD20 monoclonal antibody Ofatumumab or Arzerra in Chronic Lymphocytic Leukemia and the Histone Deacetylase inhibitor Romidepsin or Istodax in Peripheral T cell Lymphomas. Dr. Iyer has won numerous awards including Outstanding Volunteer Physician for 2010 by the Leukemia Lymphoma Society and has been listed as one of America’s Top Physicians since 2007.
Dr. Iyer received his MB, BS, from Bangalore Medical College, India. He completed his internship and residency in medicine at Wayne State University; and Fellowship in Hematology/Medical Oncology at the Sylvester Comprehensive Cancer Center, University of Miami, Florida. Soon after his fellowship, he spent many years at the Roswell Park Cancer Institute as the staff physician in Lymphoma at the Myeloma Care Center and participated in the Blood and Marrow Transplant Program. He then worked as the Director of Hematological Malignancies at the Cancer Therapy & Research Center, UTHSC, San Antonio before moving to Houston Methodist.
Dr. Iyer is a Diplomat of the American Board of Internal Medicine and is board certified in Internal Medicine, Hematology and Medical Oncology. He is currently the Leader of the Early Drug Development Program in Oncology and Hematology, and Co-Director of the Malignant Hematology Program. Dr. Iyer has extensive expertise in early phase clinical studies including several first in human anticancer agents.